

REF			SYSTEM
07026986190*	07026986500	300	<b>cobas e 402</b>
07026986214*			<b>cobas e 801</b>

\* Some kits shown may not be available in all countries.

## English

### System information

Short name	ACN (application code number)
CA125 2	10018

#### Please note

The measured CA 125 value of a patient's sample can vary depending on the testing procedure used. The laboratory finding must therefore always contain a statement on the CA 125 assay method used. CA 125 values determined on patient samples by different testing procedures cannot be directly compared with one another and could be the cause of erroneous medical interpretations. If there is a change in the CA 125 assay procedure used while monitoring therapy, then the CA 125 values obtained upon changing over to the new procedure must be confirmed by parallel measurements with both methods.

#### Intended use

Immunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma.

These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).

This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first-line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients.

This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in pre- and postmenopausal women presenting with pelvic mass.

The electrochemiluminescence immunoassay "ECLIA" is intended for use on **cobas e** immunoassay analyzers.

#### Summary

CA 125 is a repeating peptide epitope of the mucin MUC16,<sup>1,2</sup> which promotes cancer cell proliferation and inhibits anti-cancer immune responses.<sup>3,4,5,6</sup>

MAb OC 125 was an antibody obtained from mice that had been immunized with OVCA (ovarian carcinoma cell line) 433, an adenocarcinoma cell line from the ovary.<sup>7</sup> Subsequently, the MAb M11 antibody was developed against CA 125.<sup>8</sup> In the Elecsys test, OC 125 is used as a detection antibody. MAb M 11 is used as the capture antibody (solid-phase antibody); this has been employed in second-generation CA 125 assays since 1992.

CA 125 has been found in the amniotic fluid and in the coelomic epithelium; both of these tissues are of fetal origin. In tissues of adult origin, the presence of CA 125 has been demonstrated in the epithelium of the oviduct, in the endometrium and in the endocervix.<sup>9</sup>

CA 125 is found in a high percentage of ovarian tumors of epithelial origin and can be detected in serum.<sup>10,11</sup> Elevated values are sometimes found in various benign gynecological diseases such as ovarian cysts and endometriosis.<sup>12</sup> Slight elevations of this marker may also occur in early pregnancy and in various benign diseases (e.g. pancreatitis, cirrhosis, hepatitis, benign gastrointestinal diseases, renal insufficiency, and others).<sup>13</sup> Although the highest CA 125 values occur in patients suffering from ovarian carcinoma, elevated values are also observed in malignancies of the endometrium, breast, gastrointestinal tract, and various other malignancies.

Recent findings show that combination of CA 125 and HE4 can help to determine whether a pelvic mass is benign or malignant in pre- and postmenopausal women. The dual marker combination CA 125 and HE4 is a more accurate predictor of malignancy than either alone.<sup>14</sup> Huhtinen et al.

reported a 78.6 % sensitivity at 95 % specificity in ovarian carcinoma vs. endometriotic cysts.<sup>15</sup> Moore et al. reported 94 % accuracy in identifying malignant vs benign pelvic masses when combining CA 125 and HE4 in the ROMA algorithm.<sup>16</sup>

#### Test principle

Sandwich principle. Total duration of assay: 18 minutes.

- 1st incubation: 12 µL of sample, a biotinylated monoclonal CA 125-specific antibody, and a monoclonal CA 125-specific antibody labeled with a ruthenium complex<sup>a)</sup> form a sandwich complex.
- 2nd incubation: After addition of streptavidin-coated microparticles, the complex becomes bound to the solid phase via interaction of biotin and streptavidin.
- The reaction mixture is aspirated into the measuring cell where the microparticles are magnetically captured onto the surface of the electrode. Unbound substances are then removed with ProCell II M. Application of a voltage to the electrode then induces chemiluminescent emission which is measured by a photomultiplier.
- Results are determined via a calibration curve which is instrument-specifically generated by 2-point calibration and a master curve provided via the **cobas** link.

a) Tris(2,2'-bipyridyl)ruthenium(II)-complex (Ru(bpy)<sub>3</sub><sup>2+</sup>)

#### Reagents - working solutions

The **cobas e** pack is labeled as CA125 2.

- M Streptavidin-coated microparticles, 1 bottle, 14.1 mL:  
Streptavidin-coated microparticles 0.72 mg/mL; preservative.
- R1 Anti-CA 125-Ab-biotin, 1 bottle, 18.8 mL:  
Biotinylated monoclonal anti-CA 125 antibody (M 11; mouse) 1 mg/L;  
phosphate buffer 100 mmol/L, pH 7.4; preservative.
- R2 Anti-CA 125-Ab-Ru(bpy)<sub>3</sub><sup>2+</sup>, 1 bottle, 18.8 mL:  
Monoclonal anti-CA 125 antibody (OC 125; mouse) labeled with  
ruthenium complex 1 mg/L; phosphate buffer 100 mmol/L, pH 7.4;  
preservative.

#### Precautions and warnings

For in vitro diagnostic use for health care professionals. Exercise the normal precautions required for handling all laboratory reagents.

Infectious or microbial waste:

Warning: handle waste as potentially biohazardous material. Dispose of waste according to accepted laboratory instructions and procedures.

Environmental hazards:

Apply all relevant local disposal regulations to determine the safe disposal.

Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



#### Warning

- H317 May cause an allergic skin reaction.

#### Prevention:

- P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
- P272 Contaminated work clothing should not be allowed out of the workplace.

P280 Wear protective gloves.

## Response:

P333 + P313 If skin irritation or rash occurs: Get medical advice/attention.

P362 + P364 Take off contaminated clothing and wash it before reuse.

## Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling follows EU GHS guidance.

Contact phone: all countries: +49-621-7590

Avoid foam formation in all reagents and sample types (specimens, calibrators and controls).

## Reagent handling

The reagents in the kit have been assembled into a ready-for-use unit that cannot be separated.

All information required for correct operation is available via the **cobas** link.

## Storage and stability

Store at 2-8 °C.

Do not freeze.

Store the **cobas e** pack **upright** in order to ensure complete availability of the microparticles during automatic mixing prior to use.

Stability:	
unopened at 2-8 °C	up to the stated expiration date
on the analyzers	16 weeks

## Specimen collection and preparation

Only the specimens listed below were tested and found acceptable.

Serum collected using standard sampling tubes or tubes containing separating gel.

Li-heparin, K<sub>2</sub>-EDTA and K<sub>3</sub>-EDTA plasma.

Plasma tubes containing separating gel can be used.

Criterion: Slope 0.9-1.1 + coefficient of correlation  $\geq$  0.95.

Stable for 8 hours at 20-25 °C, 5 days at 2-8 °C, 24 weeks at -20 °C ( $\pm$  5 °C). Freeze only once.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Do not use heat-inactivated samples.

Do not use samples and controls stabilized with azide.

Ensure the samples and calibrators are at 20-25 °C prior to measurement.

Due to possible evaporation effects, samples and calibrators on the analyzers should be analyzed/measured within 2 hours.

## Materials provided

See "Reagents – working solutions" section for reagents.

## Materials required (but not provided)

- [REF] 07030207190, CA 125 II CalSet II, for 4 x 1.0 mL
- [REF] 11776452122, PreciControl Tumor Marker, for 4 x 3.0 mL
- [REF] 07299001190, Diluent Universal, 36 mL sample diluent
- General laboratory equipment
- **cobas e** analyzer

For epithelial ovarian cancer risk assessment with ROMA (Risk of Ovarian Malignancy Algorithm):

- [REF] 07027478190, Elecsys HE4, 100 tests

- [REF] 05950945190, HE4 CalSet, for 4 x 1 mL
- [REF] 05950953190, PreciControl HE4, for 4 x 1 mL
- [REF] 07299010190, Diluent MultiAssay, 36 mL sample diluent

Additional materials for **cobas e** 402 and **cobas e** 801 analyzers:

- [REF] 06908799190, ProCell II M, 2 x 2 L system solution
- [REF] 04880293190, CleanCell M, 2 x 2 L measuring cell cleaning solution
- [REF] 07485409001, Reservoir Cup, 8 cups to supply ProCell II M and CleanCell M
- [REF] 06908853190, PreClean II M, 2 x 2 L wash solution
- [REF] 05694302001, Assay Tip/Assay Cup tray, 6 magazines x 6 magazine stacks x 105 assay tips and 105 assay cups, 3 wasteliners
- [REF] 07485425001, Liquid Flow Cleaning Cup, 2 adaptor cups to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning Detection Unit
- [REF] 07485433001, PreWash Liquid Flow Cleaning Cup, 1 adaptor cup to supply ISE Cleaning Solution/Elecsys SysClean for Liquid Flow Cleaning PreWash Unit
- [REF] 11298500316, ISE Cleaning Solution/Elecsys SysClean, 5 x 100 mL system cleaning solution

## Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

Resuspension of the microparticles takes place automatically prior to use.

Place the cooled (stored at 2-8 °C) **cobas e** pack on the reagent manager. Avoid foam formation. The system automatically regulates the temperature of the reagents and the opening/closing of the **cobas e** pack.

## Calibration

Traceability: This method has been standardized against the Enzyun-Test CA 125 II method. This in turn has been standardized against the CA 125 II RIA from Fujirebio Diagnostics.

The predefined master curve is adapted to the analyzer using the relevant CalSet.

*Calibration frequency:* Calibration must be performed once per reagent lot using fresh reagent (i.e. not more than 24 hours since the **cobas e** pack was registered on the analyzer).

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Renewed calibration is recommended as follows:

- after 12 weeks when using the same reagent lot
- after 28 days when using the same **cobas e** pack on the analyzer
- as required: e.g. quality control findings outside the defined limits

## Quality control

For quality control, use PreciControl Tumor Marker.

In addition, other suitable control material can be used.

Controls for the various concentration ranges should be run individually at least once every 24 hours when the test is in use, once per **cobas e** pack, and following each calibration.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

If necessary, repeat the measurement of the samples concerned.

Follow the applicable government regulations and local guidelines for quality control.

## Calculation

The analyzer automatically calculates the analyte concentration of each sample (either in U/mL, U/L or kU/L).

## Limitations - interference

The effect of the following endogenous substances and pharmaceutical compounds on assay performance was tested. Interferences were tested up to the listed concentrations and no impact on results was observed.

## Endogenous substances

Compound	Concentration tested
Bilirubin	≤ 1130 μmol/L or ≤ 66 mg/dL
Hemoglobin	≤ 2.0 mmol/L or ≤ 3200 mg/dL
Intralipid	≤ 2000 mg/dL
Biotin	≤ 287 nmol/L or ≤ 70 ng/mL
Rheumatoid factors	≤ 1200 IU/mL

Criterion: For concentrations of 0.6-12 U/mL the deviation is ± 1.2 U/mL. For concentrations > 12 U/mL the deviation is ± 10 %.

Samples should not be taken from patients receiving therapy with high biotin doses (i.e. > 5 mg/day) until at least 8 hours following the last biotin administration.

There is no high-dose hook effect at CA 125 concentrations up to 50000 U/mL.

## Pharmaceutical substances

In vitro tests were performed on 16 commonly used pharmaceuticals. No interference with the assay was found.

In addition, the following special cancer drugs were tested. No interference with the assay was found.

## Special cancer drugs

Drug	Concentration tested mg/L
Carboplatin	1000
Cisplatin L	225
Cyclophosphamide	1000
Dexamethasone	20
Doxorubicin	75
Leucovorin	750
Melphalan	15
Methotrexate	1000
Paclitaxel	265
5-FU	500
Avastin	750
Tarceva	150
MabThera	750
Herceptin	600
Tamoxifen	50
Mitomycin	25
Etoposide	400
Flutamide	1000
Taxol	5.5
Gemcitabine	1500
Docetaxel	112
PEG lip.Doxorubicin	75
Lynparza	80

In rare cases, interference due to extremely high titers of antibodies to analyte-specific antibodies, streptavidin or ruthenium can occur. These effects are minimized by suitable test design.

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

## Limits and ranges

### Measuring range

0.6-5000 U/mL (defined by the Limit of Blank and the maximum of the master curve). Values below the Limit of Blank are reported as < 0.6 U/mL. Values above the measuring range are reported as > 5000 U/mL (or up to 25000 U/mL for 5-fold diluted samples).

## Lower limits of measurement

### Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = 0.6 U/mL

Limit of Detection = 1.2 U/mL

Limit of Quantitation = 2.0 U/mL

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95<sup>th</sup> percentile value from n ≥ 60 measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples. The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with an intermediate precision CV of ≤ 20 %.

An internal study was performed based on guidance from the CLSI protocol EP17-A2. Limit of Blank, Limit of Detection and Limit of Quantitation were determined to be the following:

Limit of Blank = 0.505 U/mL

Limit of Detection = 0.567 U/mL

For Limit of Quantitation ≥ 4 human serum samples were measured over 5 days in 5 replicates on one analyzer. With an intermediate precision of ≤ 20 % the Limit of Quantitation was 0.694 U/mL.

## Dilution

Samples with CA 125 concentrations above the measuring range can be diluted with Diluent Universal. The recommended dilution is 1:5 (automatically by the analyzer or manually). The concentration of the diluted sample must be ≥ 1000 U/mL.

After manual dilution, multiply the result by the dilution factor.

After dilution by the analyzer, the software automatically takes the dilution into account when calculating the sample concentration.

## Expected values

Studies using the Elecsys CA 125 II assay in 593 samples from healthy females (pre- and postmenopausal) yielded a value of 35 U/mL (95<sup>th</sup> percentile). Values > 35 U/mL indicate an increased probability for residual or recurrent ovarian carcinoma in patients treated for primary epithelial invasive ovarian cancer.

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

## Risk estimation in patients with pelvic mass

For risk estimation with ROMA see package insert of the Elecsys HE4 assay.

## Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

## Precision

Precision was determined using Elecsys reagents, samples and controls in a protocol (EP05-A3) of the CLSI (Clinical and Laboratory Standards Institute): 2 runs per day in duplicate each for 21 days (n = 84). The following results were obtained:

cobas e 402 and cobas e 801 analyzers					
Sample	Mean U/mL	Repeatability		Intermediate precision	
		SD U/mL	CV %	SD U/mL	CV %
Human serum 1	1.58	0.0427	2.7	0.0541	3.4

# Elecsys CA 125 II

cobas e 402 and cobas e 801 analyzers					
		Repeatability		Intermediate precision	
Sample	Mean U/mL	SD U/mL	CV %	SD U/mL	CV %
Human serum 2	2.38	0.0457	1.9	0.0654	2.8
Human serum 3	34.3	0.384	1.1	0.650	1.9
Human serum 4	2338	33.9	1.5	56.2	2.4
Human serum 5	3975	42.8	1.1	112	2.8
PreciControl TM <sup>b)</sup> 1	29.1	0.452	1.6	0.619	2.1
PreciControl TM2	90.4	1.29	1.4	1.70	1.9

b) TM = Tumor Marker

## Method comparison

A comparison of the Elecsys CA125 II assay, [REF] 07026986190 (cobas e 801 analyzer; y) with the Elecsys CA125 II assay, [REF] 11776223190 (cobas e 601 analyzer; x) gave the following correlations U/mL:

Number of samples measured: 163

Passing/Bablok<sup>17</sup> Linear regression  
 $y = 0.962x - 0.647$   $y = 1.012x - 11.1$   
 $r = 0.993$   $r = 0.999$

The sample concentrations were between 1.50 and 4695 U/mL.

A comparison of the Elecsys CA125 II assay, [REF] 07026986190 (cobas e 402 analyzer; y) with the Elecsys CA125 II assay, [REF] 07026986190 (cobas e801 analyzer; x) gave the following correlations U/mL:

Number of samples measured: 179

Passing/Bablok<sup>17</sup> Linear regression  
 $y = 0.971x - 0.099$   $y = 0.978x - 1.94$   
 $r = 0.994$   $r = 1.00$

The sample concentrations were between 0.809 and 4938 U/mL.

## Analytical specificity

The Elecsys CA 125 II tumor marker assay is based on the monoclonal M 11 and OC 125 antibodies which are only available from Fujirebio Diagnostics, its licensees and its representatives. The performance characteristics of test procedures using these antibodies cannot be assumed for test methods using other antibodies.

## References

- O'Brien TJ, Beard JB, Underwood LJ, et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences. *Tumor Biol* 2001;22(6):348-366.
- Yin BW, Lloyd KO. Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16. *J Biol Chem* 2001;276(29):27371-27375.
- Rump A, Morikawa Y, Tanaka M, et al. Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. *J Biol Chem* 2004;279(10):9190-9198.
- Hattrop CL, Gendler SJ. Structure and function of the cell surface (Tethered) Mucins. *Annu Rev Physiol* 2007;70:431-457.
- Comamala M, Pinar M, Theriault C, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH: OVCAR3 ovarian carcinoma cells. *Br J Cancer* 2011;104(6):989-999.
- Bast RC Jr, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. *Gynecol Oncol* 2011;121:429-430.
- Davis HM, Zurawski VR Jr, Bast RC Jr, et al. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. *Cancer Research* 1986;46:6143-6148.

- O'Brien TJ, Raymond LM, Bannon GA, et al. New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope. *Am J Obstet Gynecol* 1991;165(6):1857-1864.
- Kawat SE, Bast RC Jr, Bhan AK, et al. Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC 125. *Int J Gyn Path* 1983;2:275-285.
- Bast RC, Klug TL, St. John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. *N Engl J Med* 1983;309:883-887.
- Klug TL, Bast RC Jr, Niloff JM, et al. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. *Cancer Res* 1984;44:1048-1053.
- Moore RG, Miller MC, Steinhoff MM, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. *Am J Obstet Gynecol*. 2012;206(4): 351.e1-8.
- Daoud E, Bodor G, Weaver Ch, et al. (Washington University Case Conference) CA-125 Concentrations in Malignant and Nonmalignant Disease. *Clin Chem* 1991;37(11):1968-1974.
- Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. *Gynecol Oncol* 2008;108(2):402-408.
- Huhtinen K, Suvitie P, Hlissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. *Br J Cancer* 2009;100(8):1315-1319.
- Moore RG, Miller MC, Skates SJ, et al. Evaluation of the Diagnostic Accuracy of the Risk of Ovarian Malignancy Algorithm in Women With a Pelvic Mass. *Obstet Gynecol*. 2011;118 (2, Part 1):280-288.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. *J Clin Chem Clin Biochem* 1988 Nov;26(11):783-790.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets and the Method Sheets of all necessary components (if available in your country).

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.



CA 125 is a registered trademark of Fujirebio Diagnostics, Inc.

Any serious incident that has occurred in relation to the device shall be reported to the manufacturer and the competent authority of the Member State in which the user and/or the patient is established.

The Summary of Safety & Performance Report can be found here: <https://ec.europa.eu/tools/eudamed>

## Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see [dialog.roche.com](http://dialog.roche.com) for definition of symbols used):

	Contents of kit
	Analyzers/Instruments on which reagents can be used
	Reagent
	Calibrator
	Volume for reconstitution
	Global Trade Item Number

COBAS, COBAS E, ELECSYS and PRECICONTROL are trademarks of Roche. INTRALIPID is a trademark of Fresenius Kabi AB.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2022, Roche Diagnostics

07026986500V8.0

# Elecsys CA 125 II

cobas®

CE 0123



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim  
[www.roche.com](http://www.roche.com)

+800 5505 6606

